Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial

详细信息    查看全文

• 作者：Philip van Kerrebroeck ; Christopher Chapple ; Ted Drogendijk ; Monique Klaver ; Roman Sokol ; Mark Speakman ; Klaudia Traudtner ; Marcus J. Drake ; on behalf of the NEPTUNE Study Group
• 关键词：Lower urinary tract symptoms ; Solifenacin ; Storage symptoms ; Tamsulosin OCAS ; Voiding symptoms
• 刊名：European Urology
• 出版年：December, 2013
• 年：2013
• 卷：64
• 期：6
• 页码：1003-1012
• 全文大小：2156 K

文摘

Background

Storage symptoms are particularly bothersome in men with lower urinary tract symptoms (LUTS) but may not be adequately treated by 伪-blocker monotherapy.

Objective

To assess the efficacy and safety of a fixed-dose combination (FDC) of solifenacin and an oral controlled absorption system (OCAS) formulation of tamsulosin compared with placebo and compared with tamsulosin OCAS (TOCAS) monotherapy in men with moderate to severe storage symptoms and voiding symptoms.

Design, setting, and participants

A double-blind 12-wk phase 3 study in 1334 men with storage and voiding LUTS: total International Prostate Symptom Score (IPSS) 鈮?3, maximum urinary flow rate (Q_max) 4.0-12.0 ml/s, two or more urgency episodes per 24聽h of Patient Perception of Intensity of Urgency Scale grade 3 or 4, and eight or more micturitions per 24 h.

Intervention

Patients were randomised to placebo, TOCAS 0.4 mg, FDC solifenacin 6 mg plus TOCAS 0.4 mg, or FDC solifenacin 9 mg plus TOCAS 0.4 mg.

Outcome measurements and statistical analysis

Primary efficacy end points were (1) total IPSS and (2) Total Urgency and Frequency Score (TUFS). An FDC met the success criteria if it demonstrated superiority compared with placebo and noninferiority compared with TOCAS for total IPSS, as well as superiority compared with TOCAS for TUFS.

Results and limitations

Reductions in total IPSS and TUFS were observed with both solifenacin 6 mg plus TOCAS (鈭?.0 and 鈭?.1, respectively) and solifenacin 9 mg plus TOCAS (鈭?.5 and 鈭?.6, respectively) compared with TOCAS (鈭?.2 and 鈭?.7, respectively) and placebo (鈭?.4 and 鈭?.4, respectively). Solifenacin 6 mg plus TOCAS met all prespecified success criteria for both primary end points, while solifenacin 9 mg plus TOCAS met success criteria compared with placebo but not compared with TOCAS. Both FDCs improved quality of life (QoL) measures and were well tolerated, with low incidences of acute urinary retention.

Conclusions

The FDC of solifenacin 6 mg plus TOCAS significantly improved storage and voiding symptoms, as well as QoL parameters, compared with placebo. This FDC also improved storage symptoms and QoL compared with TOCAS alone in men with moderate to severe storage symptoms and voiding symptoms, and it was well tolerated.

Trial registration

ClinicalTrials.gov Identifier: ).